Comparative controlled trial of a novel oral estrogen therapy, estradiol acetate, for relief of menopause symptoms

Menopause

Volumn 12, Issue 6, 2005, Pages 708-715

  Utian, Wulf H ^a,e   Speroff, Leon ^b   Ellman, Herman ^c   Dart, Clint ^d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Warner Chilcott Inc   (United States)

^d Health Decisions Inc   (United States)

^e North American Menopause Society   (United States)

Author keywords

Estradiol acetate; Estrogen; Hormone therapy; Menopause; Vasomotor symptoms

Indexed keywords

ESTRADIOL ACETATE; ESTRADIOL DERIVATIVE; ESTROGEN; UNCLASSIFIED DRUG;

ADRENERGIC SYSTEM; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; ESTROGEN THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; RANDOMIZED CONTROLLED TRIAL; UROGENITAL TRACT DISEASE; VASOMOTOR DISORDER;

ADULT; AGED; ANALYSIS OF VARIANCE; BIOPSY; DOUBLE-BLIND METHOD; DRUG COMPOUNDING; ESTRADIOL; ESTROGENS, CONJUGATED (USP); FEMALE; FEMALE UROGENITAL DISEASES; HOT FLASHES; HUMANS; MENOPAUSE; MIDDLE AGED; PRODRUGS; TREATMENT OUTCOME;

EID: 27944479627     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gme.0000184220.63459.a8     Document Type: Article

References (20)

1. The North American Menopause Society. Recommendations for estrogen and progestogen use in peri- and postmenopausal women: October 2004 position statement of The North American Menopause Society. Menopause 2004;11:589-596.
2. Hulley SB, Grady D. The WHI estrogen-alone trial - do things look any better? JAMA 2004;291:1769-1771.
3. Avis NE, Crawford SL, McKinlay SM. Psychosocial, behavioral, and health factors related to menopause symptomatology. Womens Health 1997;3:103-120.
4. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
5. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004;291:1701-1712.
6. Grady D, Herrington D, Bittner V, et al. for the HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS-II). JAMA 2002;288:49-57.
7. Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;75:1065-1079.
8. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effects of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002;287:2668-2676.
9. Al-Azzawi F, Buckler HM, for the United Kingdom Vaginal Ring Investigator Group. Comparison of a novel vaginal ring delivering estradiol acetate versus oral estradiol for relief of vasomotor menopausal symptoms. Climacteric 2003;6:118-127.
10. Buckler H, Al-Azzawi F. The UK VR Multicentre Trial Group. The effect of a novel vaginal ring delivering oestradiol acetate on climacteric symptoms in postmenopausal women. BJOG 2003;110:753-759.
11. Speroff L. Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms. Obstet Gynecol 2003;102:823-834.
12. McNamee B, deVries T. Improved estradiol bioavailability following oral administration of a novel estradiol prodrug, estradiol acetate, in healthy postmenopausal women. AAPS Pharm Sci 2004;6(4). Abstract T2299. Available at: http://www.aapspharmsci.org.
13. McNamee B, deVries T. Pharmacokinetic characterization of a novel estradiol prodrug, estradiol acetate, for treatment of postmenopausal symptoms [Abstract]. J Clin Pharmacol 2004;44:1185-1213.
14. von Holst T, Lang E, Winkler U, Keil D. Bleeding patterns in peri and postmenopausal women taking a continuous combined regimen of estradiol with norethisterone acetate or a conventional sequential regimen of conjugated equine estrogens with medrogestone. Maturitas 2002;43:265-275.
15. Odmark IS, Backstrom T, Jonsson B, Bixo M. Long-term effects of two different continuous combined regimens of hormone replacement therapy on well-being. Gynecol Endocrinol 2004;18:305-317.
16. Guidance for Industry. Estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms. Recommendations for Clinical Evaluation: Draft Guidance, January 2003. Available at www.fda.gov/cder/infopage/estrogens_progestins/default.htm. Accessed November 12, 2004.
17. Hammond DO. Cytological assessment of climacteric patients. Clin Obstet Gynecol 1977;4:49-70.
18. Hustin J, Van den Eynde J-P. Cytologic evaluation of the effect of various estrogens given in postmenopause. Acta Cytol 1977;21:225-228.
19. Speroff L, Ellman H, Gilbert R. Efficacy and safety of a new estradiol acetate (EA) formulation for relief of vasomotor and urogenital symptoms [Abstract P-104]. Menopause 2003;10:595.
20. Nelson HD. Commonly used types of postmenopausal estrogen for treatment of hot flashes. JAMA 2002;291:1610-1620.